4 news items
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
CRDF
JNJ
NTBL
9 May 24
important new data sets supporting our first-line RAS-mutated mCRC strategy and the broader opportunity for onvansertib," said
Notable Labs Reports 2023 Financial Results and Provides a Business Update
NTBL
12 Apr 24
targeted in-licensing strategy and decision making, Notable will utilize PPMP to predict volasertib-responsive patients prior to their treatment
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
NTBL
9 Apr 24
in-licensing strategy and decision making, Notable will utilize PPMP to predict volasertib-responsive patients prior to their treatment, with the goal
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
NTBL
8 Apr 24
that work best for them. Notable believes it has created a targeted and de-risked in-licensing strategy to deliver a product's
- Prev
- 1
- Next